ZYMERON CORPORATION — Department of Defense STTR Phase I: CBD20A-T001
ZYMERON CORPORATION — STTR Phase I award from Department of Defense.
Phase I STTR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $167,497. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code CBD20A-T001 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $167,497
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- STTR · Phase I
- Topic
- CBD20A-T001
- Solicitation
- 20.A
- NAICS
- —
- Place of performance
- NC
- Period
- 2021-01-08 → 2021-06-10
Description
There is an immediate need for the U.S. Department of Defense to rapidly map large area surfaces (i.e. military vehicles, individual protective equipment, clandestine labs, etc.) potentially contaminated by trace amounts of opioids (i.e. 0.1 mg/m2). This capability will allow proper decontamination or avoidance of the contaminated areas to reduce the health risk to military personnel and first responders. Currently, there is no technology in the commercial marketspace that is capable of identification of trace amounts of opioids in large contaminated areas. Zymeron proposes to develop a solution-based spray formulation based on water-soluble mu-opioid receptor (wsMOR) which is capable of binding trace concentrations of opioid(s) in the environment and providing amplified naked-eye visual mapping of large surfaces in less than 10 minutes.